Could less radiation be enough for some lymphoma patients?
NCT ID NCT07628738
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a lower dose of radiation can safely prevent cancer from returning in people with early-stage nasal-type NK/T-cell lymphoma who have already had a complete response to chemotherapy. Participants receive 45 Gy of radiation over five weeks, targeting the original tumor area and nearby lymph nodes. The main goal is to see how many patients remain free of local or regional recurrence two years after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
reduced-intensity radiotherapy
What this could lead to
If successful, this approach could offer a less toxic radiation option for certain lymphoma patients, potentially reducing side effects while maintaining cancer control.
What could go wrong
This is a small, early-phase study (39 participants) with no control group, so results may not be definitive. The reduced radiation might be less effective at preventing recurrence than standard doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA (NON-HODGKIN'S LYMPHOMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••